RenovoRx, Inc. (RNXT) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon. I will be your conference call operator today. Please note that today's call is being recorded and all participants other than management are in a listen-only mode. There will be a Q&A session following management's presentation. I will now turn the call over to Walter Pinto, Managing Director of KCSA Strategic Communications. Please go ahead. Thank you, operator, and good afternoon. Welcome everyone to the Renova Rx second quarter 2025 conference call. I'm joined today by Renova Rx leadership team including Dr. Ramten Agha, Chairman, Founder, and Chief Medical Officer, John Bagai, Chief Executive Officer, Lisa Gentry, Chief Clinical Officer, and Renal Kozak, VP Controller and Principal Accounting Officer. Before we begin, I'd like to remind everyone that statements made during today's conference call may be deemed forward-looking statements within the meaning of the safe harbor of the Privacy Securities Litigation Reform Act of 1995 and applicable federal securities laws, and that actual results may differ materially and adversely from what is contemplated by such forward-looking statements due to a variety of risks, uncertainties, and other factors. The company's forward-looking statements are based on management's current plans and assumptions and are subject to the risks and uncertainties more fully described in the company's filings with the SEC. These statements reflect management's view of current and future market conditions including but not limited to statements regarding the company's clinical trials and other research studies, timing for potential additional interim data readouts and full patient enrollment for Renova Rx's ongoing Phase III Tiger plaque clinical trials studying intra-ritorial gemcitivine, also known as IAG, and locally adv...